Department of Clinical Laboratory, Linyi City Central Hospital, Linyi, 276400, China.
Department of Clinical Laboratory, Traditional Chinese Medical Hospital of Huangdao District, Qingdao, 266000, China.
Biochem Biophys Res Commun. 2018 Jun 2;500(2):229-235. doi: 10.1016/j.bbrc.2018.04.046. Epub 2018 Apr 16.
Forkhead box R2 (FOXR2), a new member of the FOX family, is an important player in a wide range of cellular processes such as proliferation, migration, differentiation and apoptosis. Recently, FOXR2 has been reported to be implicated in cancer development. However, the biological functions of FOXR2 in non-small cell lung cancer (NSCLC) remain unclear. In this study, we investigated the specific role of FOXR2 in NSCLC. The results showed that down-regulation of FOXR2 significantly inhibited NSCLC cell proliferation and invasion in vitro and suppressed NSCLC cell growth and metastasis in vivo. In addition, the decrease in FOXR2 expression markedly reduced the protein levels of β-catenin, cyclinD1 and c-Myc and hence inactivated the Wnt/β-catenin pathway in NSCLC cells. Taken together, we concluded that FOXR2 might be considered as a promising therapeutic target for NSCLC treatment.
叉头框 R2(FOXR2)是 FOX 家族的新成员,在细胞增殖、迁移、分化和凋亡等多种细胞过程中发挥着重要作用。最近有报道称,FOXR2 与癌症的发生发展有关。然而,FOXR2 在非小细胞肺癌(NSCLC)中的生物学功能尚不清楚。在本研究中,我们探讨了 FOXR2 在 NSCLC 中的具体作用。结果表明,下调 FOXR2 可显著抑制 NSCLC 细胞的体外增殖和侵袭,并抑制 NSCLC 细胞的体内生长和转移。此外,FOXR2 表达的降低显著降低了 NSCLC 细胞中β-catenin、cyclinD1 和 c-Myc 的蛋白水平,从而使 Wnt/β-catenin 通路失活。综上所述,我们认为 FOXR2 可能被视为 NSCLC 治疗的一种有前途的治疗靶点。